Side-by-side comparison of AI visibility scores, market position, and capabilities
Loyal is a veterinary biotech developing FDA-regulated longevity drugs for dogs; its lead drug LOY-001 received FDA reasonable expectation of effectiveness — the first longevity drug for any species to do so; raised $45M; founded by Celine Halioua.
Loyal is a veterinary biotechnology company founded in 2020 by Celine Halioua and headquartered in San Francisco, California. The company is developing pharmaceutical treatments designed to extend the healthspan and lifespan of dogs — large breeds in particular, which age faster and live shorter lives than small breeds. Loyal's approach is grounded in the biology of aging: targeting the hormonal, metabolic, and cellular mechanisms that drive age-related decline in dogs, with the goal of creating FDA-approved drugs that add healthy years to companion animals' lives.
Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.